Jefferies Financial Group Inc. Has $13.08 Million Holdings in IDEXX Laboratories, Inc. $IDXX

Jefferies Financial Group Inc. decreased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 20,465 shares of the company’s stock after selling 1,173 shares during the period. Jefferies Financial Group Inc.’s holdings in IDEXX Laboratories were worth $13,075,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. WealthCollab LLC bought a new stake in IDEXX Laboratories during the 2nd quarter worth approximately $30,000. J.Safra Asset Management Corp acquired a new stake in IDEXX Laboratories during the 3rd quarter valued at $31,000. Armstrong Advisory Group Inc. raised its position in IDEXX Laboratories by 55.9% in the 3rd quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock valued at $34,000 after purchasing an additional 19 shares during the last quarter. Salomon & Ludwin LLC bought a new position in IDEXX Laboratories in the 3rd quarter valued at $35,000. Finally, Greykasell Wealth Strategies Inc. acquired a new position in IDEXX Laboratories in the third quarter worth $35,000. Institutional investors own 87.84% of the company’s stock.

Insider Activity

In other news, EVP Nimrata Hunt sold 1,758 shares of IDEXX Laboratories stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total transaction of $1,115,574.06. Following the completion of the sale, the executive vice president owned 18,141 shares in the company, valued at $11,511,734.37. The trade was a 8.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP George Fennell sold 11,345 shares of the business’s stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the sale, the executive vice president directly owned 9,823 shares of the company’s stock, valued at approximately $6,352,730.56. This trade represents a 53.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 45,957 shares of company stock worth $29,862,109. Corporate insiders own 0.98% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on IDXX. Weiss Ratings cut IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. Wall Street Zen cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. BTIG Research reduced their price target on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research report on Tuesday, February 3rd. UBS Group decreased their price objective on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a report on Tuesday, February 3rd. Finally, Piper Sandler lowered their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research report on Monday, February 9th. Seven analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and an average target price of $783.33.

IDEXX Laboratories Stock Down 1.7%

NASDAQ IDXX opened at $608.41 on Monday. The stock has a market capitalization of $48.44 billion, a P/E ratio of 46.55, a price-to-earnings-growth ratio of 3.69 and a beta of 1.66. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $769.98. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. The stock has a fifty day moving average of $666.94 and a 200-day moving average of $668.62.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.93 by ($0.01). The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The company’s revenue was up 14.3% compared to the same quarter last year. During the same period last year, the company earned $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, equities research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.